In 2018, sales of branded biologics in immunology exceeded $64 billion across the major markets (United States, EU5, and Japan). Sales of biosimilars in these same therapy areas and regions totaled approximately $3 billion. Throughout our 2018-2028 forecast period, increasing numbers of branded biologics within the immunology space are set to lose patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and region.

Table of contents

  • Immunology
    • Market Forecast in the Major Pharmaceutical Markets
      • Terminology
    • Overarching Forecast Assumptions
      • Overview of Immune Biological Brands in Forecast
        • Biosimilar Entry Assumptions for Immune Biologics
      • Overview of Biosimilars in Immune Disease Assumptions
    • Drug-Specific Forecast Assumptions
      • Remicade
        • Forecast Assumptions
        • Patient Share by Specialty: Remicade
        • Market Forecast: Remicade
      • Enbrel
        • Forecast Assumptions
        • Patient Share by Specialty: Enbrel
        • Market Forecast: Enbrel
      • Rituxan / MabThera
        • Forecast Assumptions
        • Market Forecast for Rituxan / MabThera: Immunology
        • Market Forecast for Rituxan / MabThera: Immunology and Oncology
      • Humira
        • Forecast Assumptions
        • Patient Share by Specialty: Humira
        • Market Forecast: Humira
      • Actemra / RoActemra
        • Forecast Assumptions
        • Patient Share: RoActemra / Actemra
        • Market Forecast: Actemra / RoActemra
      • Stelara
        • Forecast Assumptions
        • Patient Share by Specialty: Stelara
        • Market Forecast: Stelara
      • Cimzia
        • Forecast Assumptions
        • Patient Share by Specialty: Cimzia
        • Market Forecast: Cimzia
      • Simponi
        • Forecast Assumptions
        • Patient Share by Specialty: Simponi
        • Market Forecast: Simponi
      • Orencia
        • Forecast Assumptions
        • Patient Share: Orencia
        • Market Forecast: Orencia
      • Cosentyx
        • Forecast Assumptions
        • Patient Share by Specialty: Cosentyx
        • Market Forecast: Cosentyx
      • Taltz
        • Forecast Assumptions
        • Patient Share by Specialty: Taltz
        • Market Forecast: Taltz
      • Tysabri
        • Forecast Assumptions
        • Patient Share by Specialty: Tysabri
        • Market Forecast: Tysabri
      • Entyvio
        • Forecast Assumptions
        • Patient Share by Specialty: Entyvio
        • Market Forecast: Entyvio

Author(s): Marta Delgado, PhD

Marta Delgado, is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a in Molecular Neuroscience from University College of London (UCL) and a in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.